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Abstract 
Review on t(2;9)(p23;q33) TRAF1/ALK, with data 
on clinics, and the genes implicated. 
Clinics and pathology 
Disease 
Anaplastic large cell lymphoma, ALK-positive 
Phenotype/cell stem origin 
Mature (peripheral) T cell. 
Etiology 
No etiologic factors are known. 
Epidemiology 
The single reported case occurred in an adult male 
(Feldman et al., 2013). 
Clinics 
Presentation in the single reported case was with 
lymphadenopathy and rash. 
Pathology 
The pathologic findings in the single reported case 
were typical for the so-called "lymphohistiocytic 
pattern" previously reported in ALK-positive 
ALCLs. 
Treatment 
The patient in the reported case was treated with  
 
anthracycline-based multi-agent chemotherapy. 
Prognosis 
Among peripheral T-cell lymphomas, ALK-
positive ALCLs tend to have favorable outcomes. 
The patient in the reported case had a recurrence 
requiring additional therapy, but was alive without 
evidence of disease at last follow-up, 28 years after 
diagnosis. 
Cytogenetics 
Note 
Deep RNA sequencing of tumor tissue identified a 
chimeric transcript fusing the end of exon 6 of 
TRAF1 to the start of exon 20 of ALK.  
The TRAF1-ALK fusion transcript was confirmed 
at the mRNA level by Sanger sequencing and the 
encoded fusion protein was visualized by Western 
blot. 
Cytogenetics morphological 
Karyotypic findings have not been reported. 
Additional anomalies 
Unknown. 
Variants 
Unknown. 
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ALCL, ALK-positive, with t(2;9)(p23;q33) TRAF1/ALK. H&E stain of paraffin embedded tumor tissue shows large atypical cells 
with cytologic features of "hallmark" cells characteristic of ALCL. Immunohistochemical staining for CD30 shows strong positivity 
in the tumor cells, with a membranous and Golgi zone distribution. Staining for ALK shows strong cytoplasmic positivity without 
nuclear staining. The absence of nuclear staining is characteristic for an alternate (non-NPM1) ALK fusion partner. TRAF1 was 
identified as the partner gene by RNA sequencing. 
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Genes involved and 
proteins 
TRAF1 
Location 
9q33.2 
Protein 
TRAF1 encodes the TRAF1 protein, a member of 
the tumor necrosis factor receptor-associated factor 
family of signaling proteins. TRAF1 associates 
with, and mediates signal transduction from, 
various receptors of the TNFR superfamily. TRAF1 
and TRAF2 form a heterodimeric complex, which 
is required for TNF-alpha-mediated activation of 
MAPK8/JNK and NF-kappaB. 
ALK 
Location 
2p23.2 
Protein 
ALK encodes a receptor tyrosine kinase, the 
anaplastic lymphoma kinase (ALK), which belongs 
to the insulin receptor superfamily and is critical in 
the development of the brain. ALK fusion proteins 
are critical in the pathogenesis of ALK-positive 
ALCLs and a variety of other hematopoietic and 
non-hematopoietic neoplasms, in which they serve 
both as a diagnostic biomarker and potential  
 
 
therapeutic target. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Expressed, as demonstrated by next-generation and 
Sanger sequencing. 
Fusion protein 
Note 
The TRAF1-ALK fusion transcript and TRAF1-
ALK fusion protein both were expressed in the 
reported case.  
The function of the fusion has not been reported. 
Description 
Expressed, as demonstrated by Western blot and 
immunohistochemistry. 
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